The cancer stem cell (CSC) paradigm emerged from investigating a subpopulation of less-differentiated CD34+/CD38- cells possessing stem cell-like renewal ability and robust malignant-initiating capacity in acute myeloid leukemia (AML)[1]. This evidence concerns the gene CD38 and acute myeloid leukemia.